The evolution of stent technology over the past two decades

Coronary stent technology has evolved from bare-metal scaffolds into a family of thinner, drug-releasing, and increasingly specialized devices designed to keep narrowed arteries open while reducing complications. Over roughly two decades, improvements in stent materials, drug coatings, delivery systems, and clinical decision-making have lowered risks such as restenosis and stent thrombosis for many patients. The change is measurable: contemporary drug-eluting stents (DES) generally perform better than early-generation devices, while newer approaches—including bioresorbable scaffolds and image-guided implantation—address limitations that metal stents cannot fully remove. These advances matter because coronary artery disease remains a major global health burden, and percutaneous coronary intervention (PCI) is performed millions of times each year.

Coronary Stent Design and Material Evolution

A coronary stent is a small expandable scaffold placed inside a coronary artery to restore or maintain blood flow. The U.S. National Heart, Lung, and Blood Institute describes stents as mesh tubes that help keep arteries open, commonly placed during angioplasty. Modern stent engineering balances radial strength, flexibility, deliverability, visibility on imaging, and compatibility with the vessel’s healing response. The main design categories are bare-metal stents, drug-eluting stents, and bioresorbable scaffolds.

From Bare-Metal Stents to Thinner Struts

Bare-metal stents (BMS) are metallic scaffolds without an antiproliferative drug coating. They improved on balloon angioplasty alone by reducing abrupt vessel closure and elastic recoil, but tissue growth inside the stent could cause restenosis—the re-narrowing of the treated segment. The first-generation DES addressed this problem by releasing drugs that suppress excessive smooth-muscle-cell growth. Later devices also reduced strut thickness, refined stent geometry, and improved flexibility. Thinner struts can disturb blood flow less and may reduce vessel injury, although the full clinical effect depends on the device, lesion, and patient.

Drug-Eluting Stents and Polymer Coatings

A drug-eluting stent combines a metal scaffold with an antiproliferative medicine delivered locally to limit neointimal tissue growth. The drugs most commonly used in contemporary coronary DES are “limus” agents, including everolimus, zotarolimus, and biolimus. Early DES commonly used durable polymers to control drug release; these coatings could remain after the drug had been delivered and were investigated as one possible contributor to inflammation or delayed healing. Newer designs use more biocompatible durable polymers, polymer-free drug delivery, or biodegradable polymers that break down after releasing the drug. The European Society of Cardiology’s 2018 myocardial revascularization guideline recommends new-generation DES over BMS for most patients undergoing PCI.

Bioresorbable Scaffolds

Bioresorbable vascular scaffolds are intended to provide temporary support and then gradually dissolve, potentially leaving no permanent metallic implant. The concept addresses a genuine limitation of permanent stents: a metal cage can constrain vessel movement and complicate future procedures. However, early clinical experience showed that theoretical advantages do not guarantee safer outcomes. In the five-year ABSORB III trial, the Absorb scaffold had more target-lesion failure than cobalt-chromium everolimus-eluting stents—17.5% versus 14.5%—and more device thrombosis, 2.5% versus 0.8%. The U.S. Food and Drug Administration noted these risks in its safety communications, and the first-generation Absorb device was withdrawn from commercial sale. Bioresorbable technology remains an active research area, but routine use requires evidence that a scaffold’s long-term benefits outweigh its early mechanical risks.

Clinical Performance and Safety of Modern Stents

Stent performance is judged not only by whether an artery remains open, but also by rates of heart attack, repeat revascularization, bleeding, and stent thrombosis. Contemporary DES have substantially reduced restenosis compared with BMS and older-generation DES. The specific outcome depends on patient risk, lesion complexity, implantation technique, and the duration of antiplatelet treatment. This shift has made device selection and individualized follow-up as important as the scaffold itself.

Restenosis, Thrombosis, and Repeat Procedures

Restenosis is typically driven by tissue growth and vessel remodeling within or near the treated segment; stent thrombosis is the formation of a clot inside the device and can cause a sudden heart attack. In the large randomized NORSTENT trial, published in the New England Journal of Medicine in 2016, 9,013 patients were assigned to contemporary DES or BMS. At six years, the combined rate of death or nonfatal spontaneous myocardial infarction was 16.6% with DES and 17.1% with BMS, a difference that was not statistically significant. However, repeat revascularization was lower with DES—16.5% versus 19.8%—and definite stent thrombosis was also lower, 0.8% versus 1.2%. These results illustrate a central point in stent evolution: improvements may reduce device-related events and repeat procedures without necessarily changing every long-term outcome.

Antiplatelet Therapy and Shorter Treatment Strategies

Dual antiplatelet therapy (DAPT), usually aspirin plus a P2Y12 inhibitor, reduces clotting risk after stent placement but increases bleeding risk. Better healing and lower thrombosis rates with newer DES have supported trials of shorter DAPT courses for selected patients, especially those at high bleeding risk. In the 2015 LEADERS FREE trial, a polymer-free drug-coated stent was studied in patients at high bleeding risk who received one month of DAPT. At 390 days, the primary safety outcome occurred in 9.4% of patients receiving the drug-coated stent and 12.9% receiving a BMS; clinically driven target-lesion revascularization occurred in 5.1% and 9.8%, respectively. Treatment duration must still be individualized: patients should not stop prescribed antiplatelet medicines without advice from their treating clinician.

Complex Lesions and Patient-Specific Choices

Modern DES are used in a broad range of settings, including diabetes, long or calcified lesions, bifurcations, and some left-main coronary disease. The best strategy depends on anatomy and clinical circumstances; a stent is not automatically the right treatment for every patient. For example, the EXCEL trial compared PCI using everolimus-eluting stents with coronary artery bypass grafting in selected patients with left-main disease of low or intermediate anatomical complexity. At five years, the trial’s primary composite outcome occurred in 22.0% of the PCI group and 19.2% of the surgery group, with interpretation affected by differences in outcomes and ongoing debate about endpoints. Such evidence supports shared decision-making rather than a one-device-fits-all approach.

Precision Implantation and New Directions

Stent evolution includes not only changes to the implant but also advances in how clinicians assess lesions, prepare arteries, and confirm placement. Intravascular imaging and physiological measurements can help tailor treatment, especially in complex disease. These tools connect device engineering to precision medicine: the objective is to select the right intervention, place it accurately, and minimize both ischemic and bleeding risks.

Intravascular Imaging and Physiology

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) provide images from inside the artery, helping clinicians assess vessel dimensions, plaque, stent expansion, and edge problems. Fractional flow reserve (FFR) and related pressure-based measurements help determine whether a narrowing meaningfully limits blood flow. In the 2023 ILUMIEN IV trial, OCT-guided PCI produced a larger minimum stent area than angiography-guided PCI, but the primary clinical endpoint of target-vessel failure at two years was not significantly different: 7.4% versus 8.2%. The finding shows why imaging is valuable for procedural optimization while also underscoring that improved measurements do not always translate into a statistically significant clinical advantage in every trial.

High-Pressure Deployment and Lesion Preparation

Even an advanced stent can perform poorly if it is under-expanded or placed in an inadequately prepared artery. Balloon predilation, specialty balloons, atherectomy, or intravascular lithotripsy may be used for selected calcified lesions. After implantation, high-pressure balloon inflation and imaging can help confirm expansion and apposition. The 2021 ACC/AHA/SCAI coronary revascularization guideline supports intravascular imaging to guide PCI in selected complex cases, particularly left-main or complex coronary lesions. These practices reflect a broader evolution from “stent placement” toward carefully planned and verified revascularization.

Future Materials and Personalized Treatment

Research is exploring thinner and more flexible metallic platforms, improved coatings, bioresorbable materials, and devices tailored to vessel geometry. At the same time, clinical innovation is moving toward risk-based decisions about imaging, antiplatelet duration, and revascularization. A future stent may be judged less by a single material breakthrough than by how well its design works within a complete care strategy that includes prevention, procedural precision, and long-term monitoring. No emerging design should be assumed superior until adequately powered clinical trials demonstrate meaningful improvements in patient outcomes.

Conclusion

Over the past two decades, coronary stents have progressed from bare-metal devices to thinner, drug-eluting platforms with refined polymers and improved delivery. Bioresorbable scaffolds demonstrate both the promise and difficulty of replacing permanent metal, while imaging, physiology, and better lesion preparation have made implantation more precise. Trial results show clear reductions in restenosis and repeat procedures with modern DES, but outcomes still depend on patient characteristics, anatomy, procedural quality, and appropriate antiplatelet therapy. Patients and clinicians can use this history as a reason to discuss individualized treatment choices, current evidence, and prevention of the underlying cardiovascular disease.

Sources: National Heart, Lung, and Blood Institute, “Coronary Angioplasty and Stents,” https://www.nhlbi.nih.gov/health/coronary-angioplasty; European Society of Cardiology, 2018 ESC/EACTS Guidelines on Myocardial Revascularization, https://academic.oup.com/eurheartj/article/40/2/87/5079120; Stone GW et al., “Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease,” New England Journal of Medicine, 2015, https://www.nejm.org/doi/full/10.1056/NEJMoa1509038; U.S. Food and Drug Administration, “Absorb GT1 Bioresorbable Vascular Scaffold System—Letter to Health Care Providers,” https://www.fda.gov/medical-devices/letters-health-care-providers/absorb-gt1-bioresorbable-vascular-scaffold-system-letter-health-care-providers; Bønaa KH et al., “Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease,” New England Journal of Medicine, 2016, https://www.nejm.org/doi/full/10.1056/NEJMoa1607991; Urban P et al., “Polymer-Free Drug-Coated Coronary Stents in Patients at High Bleeding Risk,” New England Journal of Medicine, 2015, https://www.nejm.org/doi/full/10.1056/NEJMoa1503943; Stone GW et al., “Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease,” New England Journal of Medicine, 2019, https://www.nejm.org/doi/full/10.1056/NEJMoa1909406; Ali ZA et al., “Optical Coherence Tomography-Guided versus Angiography-Guided PCI,” New England Journal of Medicine, 2023, https://www.nejm.org/doi/full/10.1056/NEJMoa2305861; Lawton JS et al., “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization,” Circulation, 2022, https://www.ahajournals.org/doi/10.1161/CIR.0000000000001038.